Fig. 4From: Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studiesPercentage of patients in each diagnostic category, by month, in the subgroup of patients with MOH diagnosis at baseline in PROMISE-2: A) eptinezumab 100 mg; B) eptinezumab 300 mg; C) placebo. MHDs, monthly headache days; MOH, medication-overuse headacheBack to article page